We are live on
!
Find out more
BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
1-Year Est. Return
11.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.15%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$717M
AUM Growth
–
Cap. Flow
+$692M
Cap. Flow
% of AUM
96.53%
Top 10 Holdings %
Top 10 Hldgs %
28.85%
Holding
141
New
141
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$27.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$27M |
| 3 |
Medtronic
MDT
|
+$25.8M |
| 4 |
Gilead Sciences
GILD
|
+$23.7M |
| 5 |
Abbott
ABT
|
+$23.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.25% |
| 2 | Financials | 0.88% |
| 3 | Industrials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$30.5B
| $29.9M | 4.17% |
+70,730
| New | +$27.9M |
|
|
2
Medtronic
MDT
$110B
| $26.5M | 3.7% |
+340,000
| New | +$25.8M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $26M | 3.63% |
+225,790
| New | +$27M |
|
|
4
Abbott
ABT
$183B
| $23.5M | 3.28% |
+507,000
| New | +$23.3M |
|
|
5
Gilead Sciences
GILD
$164B
| $22.9M | 3.2% |
+233,810
| New | +$23.7M |
|
|
CTRX
6
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $18.9M | 2.63% |
+250,440
| New | +$12.7M |
|
7
Amgen
AMGN
$220B
| $17.6M | 2.45% |
+109,866
| New | +$17.3M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $14.5M | 2.02% |
+48,730
| New | +$13.9M |
|
9
UnitedHealth
UNH
$375B
| $13.6M | 1.9% |
+115,000
| New | +$12.8M |
|
10
Stryker
SYK
$129B
| $13.4M | 1.87% |
+145,700
| New | +$13.6M |
|
11
Regeneron Pharmaceuticals
REGN
$79.1B
| $12.9M | 1.8% |
+28,595
| New | +$12.1M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.6M | 1.76% |
+72,746
| New | +$13.2M |
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $12.1M | 1.69% |
+140,000
| New | +$11.7M |
|
|
CYTO
14
DELISTED
Altamira Therapeutics Ltd
CYTO
| $11.6M | 1.62% |
+27
| New | +$10.9M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.6B
| $11.4M | 1.58% |
+101,000
| New | +$10.7M |
|
16
Zimmer Biomet
ZBH
$19B
| $11.2M | 1.57% |
+98,365
| New | +$11.2M |
|
17
Vertex Pharmaceuticals
VRTX
$123B
| $11M | 1.54% |
+93,500
| New | +$11.2M |
|
|
ENDP
18
DELISTED
Endo International plc
ENDP
| $10.4M | 1.45% |
+116,000
| New | +$9.7M |
|
19
Illumina
ILMN
$30.2B
| $10.3M | 1.44% |
+57,115
| New | +$10.8M |
|
20
Jazz Pharmaceuticals
JAZZ
$16.4B
| $10.1M | 1.41% |
+58,500
| New | +$10M |
|
|
STJ
21
DELISTED
St Jude Medical
STJ
| $9.88M | 1.38% |
+151,000
| New | +$10M |
|
22
Viatris
VTRS
$20.6B
| $9.79M | 1.37% |
+165,000
| New | +$9.41M |
|
|
KITE
23
DELISTED
Kite Pharma, Inc.
KITE
| $9.69M | 1.35% |
+168,000
| New | +$11.3M |
|
24
Baxter International
BAX
$14.1B
| $9.56M | 1.33% |
+256,820
| New | +$9.74M |
|
25
Centene
CNC
$33.1B
| $9.4M | 1.31% |
+265,840
| New | +$7.99M |
|
Similar funds
VFAM
MSU
PSI
SFP
MCM
NMIS
SM
ZAM
Bellevue Asset Management (Switzerland)'s Q1 2015 Portfolio in Review
Q1 2015 is the first quarter with a 13F filing on record for Bellevue Asset Management (Switzerland), which disclosed 141 positions worth $717M. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Biogen: 70,730 shares worth $29.9M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Financials and Industrials.
- Bellevue Asset Management (Switzerland)'s largest Q1 2015 buy was Biogen: 70,730 shares worth $29.9M.
- Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $717M portfolio in Q1 2015.
- Bellevue Asset Management (Switzerland) disclosed 141 positions in Q1 2015, its first 13F filing on record.
Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q1 2015, filed 14 May 2015.